Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :27784126
Publication Date : //

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.


Various complement-mediated renal disorders are treated currently with the complement inhibitor eculizumab. By blocking the cleavage of C5, this monoclonal antibody prevents cell damage caused by complement-mediated inflammation. We included 23 patients with atypical haemolytic uraemic syndrome (aHUS, n = 12), C3 glomerulopathies (C3G, n = 9) and acute antibody-mediated renal graft rejection (AMR, n = 2), treated with eculizumab in 12 hospitals in Germany. We explored the course of complement activation biomarkers and the benefit of therapeutic drug monitoring of eculizumab. Complement activation was assessed by analysing the haemolytic complement function of the classical (CH50) and the alternative pathway (APH50), C3 and the activation products C3d, C5a and sC5b-9 prior to, 3 and 6 months after eculizumab treatment. Eculizumab concentrations were determined by a newly established specific enzyme-linked immunosorbent assay (ELISA). Serum eculizumab concentrations up to 1082 μg/ml point to drug accumulation, especially in paediatric patients. Loss of the therapeutic antibody via urine with concentrations up to 56 μg/ml correlated with proteinuria. In aHUS patients, effective complement inhibition was demonstrated by significant reductions of CH50, APH50, C3d and sC5b-9 levels, whereas C5a levels were only reduced significantly after 6 months' treatment. C3G patients presented increased C3d and consistently low C3 levels, reflecting ongoing complement activation and consumption at the C3 level, despite eculizumab treatment. A comprehensive complement analysis together with drug monitoring is required to distinguish mode of complement activation and efficacy of eculizumab treatment in distinct renal disorders. Accumulation of the anti-C5 antibody points to the need for a patient-orientated tailored therapy.

Authors : Wehling C , Amon O , Bommer M , Hoppe B , Kentouche K , Schalk G , Weimer R , Wiesener M , Hohenstein B , Tönshoff B , Büscher R , Fehrenbach H , Gök Ö-N , Kirschfink M ,

Related products :

Catalog number Product name Quantity
CC-005 ProceptorTM C5-CIC, Complement C5 bound to CIC ELISA kit- measuring immune complexes and complement system activation
CC-003 ProceptorTM C3-CIC, Complement C3 bound to CIC ELISA kit- measuring immune complexes and complement system activation
CC-004 ProceptorTM C4-CIC, Complement C4 bound to CIC ELISA kit- measuring immune complexes and complement system activation
CC-001 ProceptorTM C1q-CIC, Complement C1q bound to CIC ELISA kit- measuring immune complexes and complement system activation
CC-004d ProceptorTM C4d-CIC, Complement C4d bound to CIC ELISA kit- measuring immune complexes and complement system activation
CC-003d ProceptorTM C3d-CIC, Complement C3d bound to CIC ELISA kit- measuring immune complexes and complement system activation
CC-005b-9 ProceptorTM C5-9-CIC, Complement C5b-9 bound to CIC ELISA kit- measuring immune complexes and complement system activation
HBA-010-7 Anti_human Complement Activation Blocker_2 (CAB_2). IgG fraction (monoclonal) 250 µg
MA-1301-5 Anti-human Complement Activation Blocker-2 (CAB-2). IgG fraction (monoclonal) 100
MA-1301-5 Anti_human Complement Activation Blocker_2 (CAB_2). IgG fraction (monoclonal) 100 µg
MA-1301-5 Anti_human Complement Activation Blocker_2 (CAB_2). IgG fraction (monoclonal) 100µg
IC-003 ProceptorTM IgA-CIC, Human IgA containing CIC ELISA kit- measuring immune complexes and complement system activation
IC-002 ProceptorTM IgM-CIC, Human IgM containing CIC ELISA kit- measuring immune complexes and complement system activation
IC-001 ProceptorTM IgG-CIC, Human IgG containing CIC ELISA kit- measuring immune complexes and complement system activation
20-783-74967 MOUSE ANTI HUMAN C4c - COMPLEMENT COMPONENT 4c; Basic complement C4 Monoclonal 0.1 mg
orb82272 Complement C1q protein Complement C1q is a purified protein_bioactive peptide. For research use only. 1 mg
IHM-COMPL Animal Biologicals Complement Serum Complement Preserved Syrian Gold Hamster 25ml
IHM-COMPL Animal Biologicals Complement Serum Complement Preserved Syrian Gold Hamster 10ml
IHM-COMPL Animal Biologicals Complement Serum Complement Preserved Syrian Gold Hamster 5ml
AS10 1343 Antibody: Complement C5 , Host: sheep, polyclonal, Comfirmed reactivity: human Complement C5 (5a and 5b) 0,5mg
AS10 1355 Antibody: Complement C5 , Host: goat, polyclonal, Comfirmed reactivity: human Complement C5 0,5mg
E1969m ELISA C5,Complement C5,Hc,Hemolytic complement,Mouse,Mus musculus 96T
U1969m CLIA C5,Complement C5,Hc,Hemolytic complement,Mouse,Mus musculus 96T
E1969m ELISA kit C5,Complement C5,Hc,Hemolytic complement,Mouse,Mus musculus 96T
U1969m CLIA kit C5,Complement C5,Hc,Hemolytic complement,Mouse,Mus musculus 96T


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur